A snapshot on Oct. 20 revealed that 20.3% of Solana validators, representing staked SOL, were unprepared for the upcoming Alpenglow consensus upgrade scheduled for Oct. 21. The upgrade will replace the TowerBFT voting system with Alpenglow, aiming to reduce transaction finality time from about 12.8 seconds to near 150 milliseconds. Validators must meet specific technical requirements to participate, and those without a registered BLS key are excluded from consensus. The transition's exact impact depends on how many validators complete their setup before the epoch begins.
Solana validators with 20.3% of stake flagged before the Alpenglow upgrade provide context for crypto market activity. For readers following major cryptocurrencies on Pluang as of Oct 21, 2026 00:22 WIB, 44 of 50 major cryptos rose while 5 fell. Notable movers include SXP (Solar) down 46.27% to Rp37, COMP (Compound) up 21.54% to Rp469,285 with 68% buy orders, and THETA (Theta Network) up 18.49% to Rp3,992 with 100% sell orders.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
